查詢結果分析
來源資料
相關文獻
- Intravenous versus Intracoronary Administration of Tirofiban in Percutaneous Coronary Intervention for Acute Myocardial Infarction
- Cardiac Rupture in Patients with Acute Myocardial Infarction: Report of Three Cases and Review
- Unilateral Renal Hemorrhage Following Thrombolytic Therapy for Acute Myocardial Infarction--A Case Report
- 急性冠心症治療之新趨勢
- 以氣球擴張術或血栓溶解劑治療急性心肌梗塞的比較
- The Effect of Thrombolytic Therapy on Short-And Long-Term Cardiac Autonomic Activity in Patients with Acute Myocardial Infarction
- 血栓溶解劑導致出血性心包膜填塞--急性心肌梗塞之罕見合併症一病例報告及文獻回顧
- 緊急行動--血栓溶解療法之合併症
- 血栓溶解治療與急性心肌梗塞
- Percutaneous Transluminal Coronary Angioplasty After Thrombolytic Therapy in Acute Myocardial Infarction
頁籤選單縮合
題 名 | Intravenous versus Intracoronary Administration of Tirofiban in Percutaneous Coronary Intervention for Acute Myocardial Infarction=急性心肌梗塞經皮冠狀動脈介入性治療中使用靜脈內或冠狀動脈內推注Tirofiban的比較 |
---|---|
作 者 | 楊宇佳; 黃啟宏; 周栢青; 秦智輝; 王榮添; 邱恆正; | 書刊名 | 輔仁醫學期刊 |
卷 期 | 14:3 2016.09[民105.09] |
頁 次 | 頁117-128 |
分類號 | 415.3161 |
關鍵詞 | 急性心肌梗塞; 主要心臟不良事件; 經皮冠狀動脈介入性治療; 血栓溶解; Acute myocardial infarction; Major adverse cardiac events; Percutaneous coronary intervention; Thrombolysis; Tirofiban; |
語 文 | 英文(English) |
中文摘要 | 實驗目的:本實驗的目的是要比較急性心肌梗塞經皮冠狀動脈介入性治療中使用冠狀動脈內和靜脈內推注Tirofiban的主要心臟不良事件暨治療後的併發症。實驗方法和結果:我們回顧2001年1月至2002年12月間發生急性心肌梗塞並接經皮冠狀動脈介入性治療的106位病人的病歷。在這些病人中,50位接受冠狀動脈內推注Tirofiban(10μg/kg),56位接受靜脈內推注Tirofiban(10μg/kg)。所有病人皆接受為期兩年每個月的追蹤。兩組病人中無發生主要心臟不良事件的比例分別為冠狀動脈內注射組0.72(95% CI=0.60, 0.85)和靜脈注射組0.57(95% CI=0.43, 0.71),P值大於0.05。有高血壓,腎臟疾病,高白血球數量,較高的Killip等級和心率較快的病人發生主要心臟不良事件的風險明顯較高。結論:急性心肌梗塞并接受經皮冠狀動脈介入性治療的病人,接受冠狀動脈內推注Tirofiban的不良心臟事件發生率和靜脈內推注Tirofiban是相似的。 |
英文摘要 | Purpose: The purpose of this study was to compare intracoronary and intravenous bolus administration of tirofiban during emergency percutaneous coronary intervention for acute myocardial infarction in terms of major adverse cardiac events and post-procedural complications. Methods and Results: The medical records of 106 patients with acute myocardial infarction who underwent percutaneous coronary interventions between January 2001 and December 2002 were retrospectively reviewed. Of these patients, 50 received an intracoronary bolus of tirofiban (10 μg/kg), and 56 received an intravenous bolus of tirofiban (10 μg/kg). All patients were followed up monthly for a period of 2 years. The proportions of patients who were free of major adverse cardiac events in the intracoronary and intravenous groups were 0.72 (95% CI = 0.60, 0.85) and 0.57 (95% CI = 0.43, 0.71), respectively (P > 0.05). Patients with hypertension, renal disease, high white blood cell count, higher Killip status, and higher heart rate had a significantly higher risk of major adverse cardiac events. Conclusions: The patients with acute myocardial infarction who underwent emergency percutaneous coronary intervention and received an intracoronary bolus of tirofiban experienced similar rates of major adverse cardiac events compared to those treated with an intravenous bolus of tirofiban. |
本系統中英文摘要資訊取自各篇刊載內容。